Aldeyra Therapeutics Inc [ALDX] stock is trading at $5.19, down -0.57%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The ALDX shares have gain 17.69% over the last week, with a monthly amount drifted -6.32%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Aldeyra Therapeutics Inc [NASDAQ: ALDX] stock has seen the most recent analyst activity on April 03, 2024, when Oppenheimer upgraded its rating to a Outperform but kept the price target unchanged to $10 for it. H.C. Wainwright started tracking the stock assigning a Buy rating and suggested a price target of $26 on February 08, 2021. Berenberg initiated its recommendation with a Buy and recommended $32 as its price target on December 16, 2020. Jefferies started tracking with a Buy rating for this stock on October 30, 2020, and assigned it a price target of $24. In a note dated October 16, 2020, BTIG Research initiated an Buy rating and provided a target price of $29 on this stock.
Aldeyra Therapeutics Inc [ALDX] stock has fluctuated between $1.14 and $7.20 over the past year. Currently, Wall Street analysts expect the stock to reach $7 within the next 12 months. Aldeyra Therapeutics Inc [NASDAQ: ALDX] shares were valued at $5.19 at the most recent close of the market. An investor can expect a potential return of 34.87% based on the average ALDX price forecast.
Analyzing the ALDX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.56, Equity is -0.72 and Total Capital is -0.92. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.32.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
For context, Aldeyra Therapeutics Inc’s Current Ratio is 2.68. In addition, the Quick Ratio stands at 2.68 and the Cash Ratio stands at 2.08.
Transactions by insiders
Recent insider trading involved Alfieri Michael, Principal Financial Officer, that happened on Aug 13 ’25 when 2500.0 shares were purchased. Chief Development Officer, Machatha Stephen completed a deal on Aug 11 ’25 to sell 22073.0 shares. Meanwhile, Officer Machatha Stephen bought 22074.0 shares on Aug 12 ’25.
